Serum Anti-p53 Antibody Levels in Lung Cancer Patients
Author Information
Author(s): Y Segawal, M Kageyama, S Suzuki, K Jinno, N Takigawa, N Fujimoto, K Hotta, K Eguchi
Primary Institution: National Shikoku Cancer Center Hospital
Hypothesis
The study aims to determine the relationship between anti-p53 antibody levels and clinical features in lung cancer patients.
Conclusion
Serum anti-p53 antibody levels are higher in lung cancer patients compared to normal volunteers and are strongly correlated with tumor histological type.
Supporting Evidence
- The median anti-p53 antibody index was 6.6 for lung cancer patients compared to 1.7 for normal volunteers.
- Significant differences in index levels were found by histology.
- High anti-p53 antibody index levels were observed for both large-cell carcinoma and small-cell carcinoma.
Takeaway
This study found that lung cancer patients have higher levels of a specific antibody in their blood, which could help doctors understand their cancer better.
Methodology
The study measured serum anti-p53 antibody levels using an enzyme-linked immunosorbent assay (ELISA) in 52 lung cancer patients and 63 normal volunteers.
Limitations
The study did not find significant differences in antibody levels based on gender, age, smoking index, or disease stage.
Participant Demographics
52 lung cancer patients (32 men, 20 women, median age 68) and 63 normal volunteers (29 men, 34 women, median age 29).
Statistical Information
P-Value
P = 0.0000
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website